Skip to main content
logo
Genix Pharmaceuticals Corporation (TSXV:GENX)
Canada flag Canada · Delayed Price · Currency is CAD
0.0200
0.00 (0.00%)
At close: Aug 21, 2026

Genix Pharmaceuticals Income Statement

Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Revenue
--00.01--
Revenue Growth
---67.19%---
Cost of Revenue
--0.180.01-0
Gross Profit
---0.180--0
Selling, General & Admin
0.110.120.150.230.180.26
Amortization of Goodwill & Intangibles
0000.540.540.52
Operating Expenses
0.110.130.180.8411.61
Operating Income
-0.11-0.13-0.36-0.83-1-1.61
Interest Expense
-0.18-0.17-0.12-0.05-0.01-0
Interest & Investment Income
000000
Currency Exchange Gain (Loss)
0.01-0-0-0.01-0.030
Other Non Operating Income (Expenses)
-0.02-0.03-0.06-0.05-0.03-0.05
EBT Excluding Unusual Items
-0.3-0.33-0.55-0.94-1.07-1.65
Asset Writedown
-0.01-0.01--3.46--
Other Unusual Items
--0.47---
Pretax Income
-0.31-0.34-0.07-4.4-1.07-1.65
Earnings From Continuing Operations
-0.31-0.34-0.07-4.4-1.07-1.65
Net Income
-0.31-0.34-0.07-4.4-1.07-1.65
Net Income to Common
-0.31-0.34-0.07-4.4-1.07-1.65
Net Income Growth
------
Shares Outstanding (Basic)
616059595959
Shares Outstanding (Diluted)
616059595959
Shares Change
2.23%0.54%---18.55%
EPS (Basic)
-0.01-0.01-0.00-0.07-0.02-0.03
EPS (Diluted)
-0.01-0.01-0.00-0.07-0.02-0.03
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Free Cash Flow
-0.1-0.12-0.19-0.22-0.22-0.43
Free Cash Flow Per Share
-0.00-0.00-0.00-0.00-0.00-0.01
Gross Margin
---26.43%--
Operating Margin
---8986.67%-6737.05%--
Profit Margin
---1806.86%-35600.34%--
Free Cash Flow Margin
---4624.54%-1787.27%--
EBITDA
--0.12-0.36-0.29-0.46-1.09
D&A For EBITDA
-000.550.540.52
EBIT
-0.11-0.13-0.36-0.83-1-1.61
Revenue as Reported
--00.01--